Key statistics
As of last trade, Ardelyx Inc (41X:FRA) traded at 4.25, 30.37% above the 52 week low of 3.26 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.25 |
---|---|
High | 4.25 |
Low | 4.25 |
Bid | 4.34 |
Offer | 4.39 |
Previous close | 4.56 |
Average volume | 28.18k |
---|---|
Shares outstanding | 236.85m |
Free float | 233.11m |
P/E (TTM) | -- |
Market cap | 1.09bn USD |
EPS (TTM) | -0.3113 USD |
Data delayed at least 15 minutes, as of Nov 13 2024 07:04 GMT.
More ▼
Announcements
- Ardelyx Responds to District Court Decision Granting Motion to Dismiss
- Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference
- Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update
- Ardelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterology’s (ACG) Annual Meeting
- Ardelyx Shares Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) at the American Society of Nephrology’s Kidney Week
- Ardelyx Announces Launch of Gut Matters: Discoveries and Innovations, a New Podcast for the IBS-C Patient Community
- Ardelyx Announces the Derek Forfang Patient Advocate Award to Recognize Advocates for the Chronic Kidney Disease Community
- Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024
- Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology’s Kidney Week
- Ardelyx Announces Publication of a Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology
More ▼